BRPI0406057B1 - Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante - Google Patents

Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante Download PDF

Info

Publication number
BRPI0406057B1
BRPI0406057B1 BRPI0406057-1A BRPI0406057A BRPI0406057B1 BR PI0406057 B1 BRPI0406057 B1 BR PI0406057B1 BR PI0406057 A BRPI0406057 A BR PI0406057A BR PI0406057 B1 BRPI0406057 B1 BR PI0406057B1
Authority
BR
Brazil
Prior art keywords
amblyomin
tumor
activity
cells
recombinant protein
Prior art date
Application number
BRPI0406057-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Marisa Chudzinski Tavassi
Durvanei Augusto Maria
Isabel De Fátima Correia Batista
Paulo Lee Ho
Original Assignee
União Química Farmacêutica Nacional S/A
Ana Marisa Chudzinski Tavassi
Fundação De Amparo À Pesquisa Do Estado De São Paulo - Fapesp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by União Química Farmacêutica Nacional S/A, Ana Marisa Chudzinski Tavassi, Fundação De Amparo À Pesquisa Do Estado De São Paulo - Fapesp filed Critical União Química Farmacêutica Nacional S/A
Priority to BRPI0406057-1A priority Critical patent/BRPI0406057B1/pt
Priority to EP05782904A priority patent/EP1799707B1/en
Priority to DK05782904.6T priority patent/DK1799707T3/da
Priority to PCT/BR2005/000185 priority patent/WO2006029492A1/en
Priority to AU2005284615A priority patent/AU2005284615B2/en
Priority to CN2005800389926A priority patent/CN101142232B/zh
Priority to CA2581001A priority patent/CA2581001C/en
Priority to ES05782904T priority patent/ES2410160T3/es
Priority to JP2007531547A priority patent/JP4980220B2/ja
Publication of BRPI0406057A publication Critical patent/BRPI0406057A/pt
Priority to US11/724,557 priority patent/US8440795B2/en
Priority to CA002680759A priority patent/CA2680759A1/en
Publication of BRPI0406057B1 publication Critical patent/BRPI0406057B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0406057-1A 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante BRPI0406057B1 (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
CN2005800389926A CN101142232B (zh) 2004-09-15 2005-09-15 Kunitz型重组抑制剂
DK05782904.6T DK1799707T3 (da) 2004-09-15 2005-09-15 Rekombineret Kunitztypeinhibitor
PCT/BR2005/000185 WO2006029492A1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
AU2005284615A AU2005284615B2 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
EP05782904A EP1799707B1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
CA2581001A CA2581001C (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor
ES05782904T ES2410160T3 (es) 2004-09-15 2005-09-15 Inhibidor recombinante de tipo Kunitz
JP2007531547A JP4980220B2 (ja) 2004-09-15 2005-09-15 Ｋｕｎｉｔｚ型組換え阻害因子
US11/724,557 US8440795B2 (en) 2004-09-15 2007-03-14 Kunitz-type recombinant inhibitor
CA002680759A CA2680759A1 (en) 2004-09-15 2008-03-14 Kunitz-type recombinant inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Publications (2)

Publication Number Publication Date
BRPI0406057A BRPI0406057A (pt) 2006-05-02
BRPI0406057B1 true BRPI0406057B1 (pt) 2021-10-26

Family

ID=36273230

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Country Status (10)

Country Link
US (1) US8440795B2 (enExample)
EP (1) EP1799707B1 (enExample)
JP (1) JP4980220B2 (enExample)
CN (1) CN101142232B (enExample)
AU (1) AU2005284615B2 (enExample)
BR (1) BRPI0406057B1 (enExample)
CA (2) CA2581001C (enExample)
DK (1) DK1799707T3 (enExample)
ES (1) ES2410160T3 (enExample)
WO (1) WO2006029492A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
AU2008226358A1 (en) * 2007-03-14 2008-09-18 Ana Marisa Chudzinski-Tavassi Kunitz-type recombinant inhibitor
EP2379096B1 (en) * 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
BR102018074043A2 (pt) * 2018-11-22 2020-06-02 Inst Butantan composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias
BR102018074037A2 (pt) * 2018-11-22 2021-05-11 Inst Butantan composto para direcionar entidades moleculares para o domínio intracelular de células neoplásicas, ingrediente farmacêutico ativo compreendendo o referido composto, composição farmacêutica, método para o diagnóstico, prognóstico e/ou tratamento de câncer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006207C2 (de) * 1980-02-15 1982-10-21 Siemens AG, 1000 Berlin und 8000 München Elektrische Maschine mit einem Ständerblechpaket aus kornorientierten Blechen
DE3819078A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Also Published As

Publication number Publication date
EP1799707B1 (en) 2013-03-27
US8440795B2 (en) 2013-05-14
CA2581001A1 (en) 2006-03-23
AU2005284615B2 (en) 2011-03-31
WO2006029492A1 (en) 2006-03-23
US20090042786A1 (en) 2009-02-12
ES2410160T3 (es) 2013-07-01
DK1799707T3 (da) 2013-05-21
JP2008512992A (ja) 2008-05-01
CA2680759A1 (en) 2008-09-18
AU2005284615A1 (en) 2006-03-23
JP4980220B2 (ja) 2012-07-18
CA2581001C (en) 2011-05-03
CN101142232A (zh) 2008-03-12
BRPI0406057A (pt) 2006-05-02
CN101142232B (zh) 2013-03-13
EP1799707A1 (en) 2007-06-27

Similar Documents

Publication Publication Date Title
Moreau et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family
Beauchamp et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation
Jiang et al. Three pairs of protease-serpin complexes cooperatively regulate the insect innate immune responses
WO2011036443A2 (en) Polypeptides and uses thereof
US8440795B2 (en) Kunitz-type recombinant inhibitor
AU2010299631A1 (en) Polypeptides and uses thereof
Randolph et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli
Gora et al. Involvement of cysteine proteases in cancer
Ranasinghe et al. A novel coagulation inhibitor from Schistosoma japonicum
Brito et al. The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models
Li et al. LCTX-F2, a novel potentiator of coagulation factors from the spider venom of Lycosa singoriensis
Huang et al. Low-dose hydralazine improves endotoxin-induced coagulopathy and multiple organ dysfunction via its anti-inflammatory and anti-oxidative/nitrosative properties
PL179215B1 (pl) sposób wytwarzania wyciagu i srodek farmaceutyczny PL PL PL PL PL PL PL PL
JP2001509367A (ja) ヒトｔｆｐｉ遺伝子を含む血管保護性組換えアデノウイルスベクター
Matrane et al. Congenital Alpha-2 Antiplasmin Deficiency: a Literature Survey and Analysis of 123 Cases.
Markwardt State-of-the-art review: Antithrombotic agents from hematophagous animals
EP2134843A1 (en) Kunitz-type recombinant inhibitor
BRPI0200269B1 (pt) processo de purificação de proteínas solúveis das cerdas da l. obliqua com atividade ativadora de protrombina e uso da fração proteica
EP1411964A2 (en) Peptides which modulate blood coagulation and methods of use thereof
TW200846356A (en) Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
Palumbo et al. Genetic analysis of hemostatic factors in cancer
Berg et al. British Society for Haemostasis and
Shen Tissue factor: getting to know an old friend
Knight The role of PAR-1, PAR-2 and Tissue factor in the development of hepatic fibrosis
Levi et al. Pathophysiology, Diagnosis and Treatment of Disseminated Intravascular Coagulation

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61P 35/00 (2010.01), A61K 38/57 (2010.01), C12N 1

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/57 (2006.01), A61P 35/00 (2006.01), C12N 1

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.